Oppenheimer Asset Management Inc. Has $4.08 Million Stake in GSK plc (NYSE:GSK)

Oppenheimer Asset Management Inc. lifted its position in shares of GSK plc (NYSE:GSK) by 11.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 105,927 shares of the pharmaceutical company’s stock after acquiring an additional 10,942 shares during the period. Oppenheimer Asset Management Inc.’s holdings in GSK were worth $4,078,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Register Financial Advisors LLC acquired a new position in GSK during the first quarter valued at approximately $31,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK during the 2nd quarter worth $37,000. Richardson Financial Services Inc. bought a new stake in shares of GSK during the 4th quarter worth $40,000. PrairieView Partners LLC acquired a new stake in GSK in the second quarter valued at about $47,000. Finally, Newbridge Financial Services Group Inc. bought a new position in GSK in the first quarter valued at about $49,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Up 1.3 %

GSK opened at $43.55 on Tuesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The company’s 50 day moving average price is $41.14 and its two-hundred day moving average price is $41.70. The firm has a market capitalization of $90.26 billion, a price-to-earnings ratio of 15.78, a PEG ratio of 1.41 and a beta of 0.66.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The business had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. As a group, research analysts predict that GSK plc will post 4.15 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be paid a dividend of $0.3843 per share. This represents a $1.54 dividend on an annualized basis and a yield of 3.53%. The ex-dividend date of this dividend is Friday, August 16th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is currently 54.71%.

Analyst Ratings Changes

GSK has been the subject of a number of research reports. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. The Goldman Sachs Group started coverage on shares of GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price objective for the company. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Finally, Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.